Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges

• Main Authors: Néstor Prieto-Dominguez, Christopher Parnell, Yong Teng
• Format: Article
• Language: English
• Published: MDPI AG 2019-03-01
• Series: Cells
• Subjects: small GTPases; Arf1; inhibitors; cancer therapy; anticancer
• Online Access: http://www.mdpi.com/2073-4409/8/3/255

Small GTPases are a family of low molecular weight GTP-hydrolyzing enzymes that cycle between an inactive state when bound to GDP and an active state when associated to GTP. Small GTPases regulate key cellular processes (e.g., cell differentiation, proliferation, and motility) as well as subcellular events (e.g., vesicle trafficking), making them key participants in a great array of pathophysiological processes. Indeed, the dysfunction and deregulation of certain small GTPases, such as the members of the Ras and Arf subfamilies, have been related with the promotion and progression of cancer. Therefore, the development of inhibitors that target dysfunctional small GTPases could represent a potential therapeutic strategy for cancer treatment. This review covers the basic biochemical mechanisms and the diverse functions of small GTPases in cancer. We also discuss the strategies and challenges of inhibiting the activity of these enzymes and delve into new approaches that offer opportunities to target them in cancer therapy.